 This randomized multicentre controlled study will include approximately 100 PAH patients NYHA II to IV. After inclusion, patients will receive either collaborative care including consultations with specialized pharmacist and nurse, or classic follow-up. Each patient will be followed during 18 months from the date of inclusion. 